Literature DB >> 25753093

The potential of translational bioinformatics approaches for pharmacology research.

Lang Li1,2,3.   

Abstract

The field of bioinformatics has allowed the interpretation of massive amounts of biological data, ushering in the era of 'omics' to biomedical research. Its potential impact on pharmacology research is enormous and it has shown some emerging successes. A full realization of this potential, however, requires standardized data annotation for large health record databases and molecular data resources. Improved standardization will further stimulate the development of system pharmacology models, using translational bioinformatics methods. This new translational bioinformatics paradigm is highly complementary to current pharmacological research fields, such as personalized medicine, pharmacoepidemiology and drug discovery. In this review, I illustrate the application of transformational bioinformatics to research in numerous pharmacology subdisciplines.
© 2015 The British Pharmacological Society.

Keywords:  big data; clinical pharmacology; systems pharmacology; translational bioinformatics

Mesh:

Year:  2015        PMID: 25753093      PMCID: PMC4594729          DOI: 10.1111/bcp.12622

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  39 in total

1.  A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports.

Authors:  Nicholas P Tatonetti; Guy Haskin Fernald; Russ B Altman
Journal:  J Am Med Inform Assoc       Date:  2011-06-14       Impact factor: 4.497

2.  Statistical Mining of Potential Drug Interaction Adverse Effects in FDA's Spontaneous Reporting System.

Authors:  Rave Harpaz; Krystl Haerian; Herbert S Chase; Carol Friedman
Journal:  AMIA Annu Symp Proc       Date:  2010-11-13

3.  Web-scale pharmacovigilance: listening to signals from the crowd.

Authors:  Ryen W White; Nicholas P Tatonetti; Nigam H Shah; Russ B Altman; Eric Horvitz
Journal:  J Am Med Inform Assoc       Date:  2013-03-06       Impact factor: 4.497

4.  Exploring a structural protein-drug interactome for new therapeutics in lung cancer.

Authors:  Xiaodong Peng; Fang Wang; Liwei Li; Khuchtumur Bum-Erdene; David Xu; Bo Wang; Anthony A Sinn; Karen E Pollok; George E Sandusky; Lang Li; John J Turchi; Shadia I Jalal; Samy O Meroueh
Journal:  Mol Biosyst       Date:  2014-01-09

5.  Proteogenomic characterization of human colon and rectal cancer.

Authors:  Bing Zhang; Jing Wang; Xiaojing Wang; Jing Zhu; Qi Liu; Zhiao Shi; Matthew C Chambers; Lisa J Zimmerman; Kent F Shaddox; Sangtae Kim; Sherri R Davies; Sean Wang; Pei Wang; Christopher R Kinsinger; Robert C Rivers; Henry Rodriguez; R Reid Townsend; Matthew J C Ellis; Steven A Carr; David L Tabb; Robert J Coffey; Robbert J C Slebos; Daniel C Liebler
Journal:  Nature       Date:  2014-07-20       Impact factor: 49.962

6.  Identifying potential adverse effects using the web: a new approach to medical hypothesis generation.

Authors:  Adrian Benton; Lyle Ungar; Shawndra Hill; Sean Hennessy; Jun Mao; Annie Chung; Charles E Leonard; John H Holmes
Journal:  J Biomed Inform       Date:  2011-07-26       Impact factor: 6.317

7.  Online discussion of drug side effects and discontinuation among breast cancer survivors.

Authors:  Jun J Mao; Annie Chung; Adrian Benton; Shawndra Hill; Lyle Ungar; Charles E Leonard; Sean Hennessy; John H Holmes
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-01-16       Impact factor: 2.890

8.  Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins.

Authors:  H Schelleman; X Han; C M Brensinger; S K Quinney; W B Bilker; D A Flockhart; L Li; Sean Hennessy
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

9.  A network pharmacology approach to determine active compounds and action mechanisms of ge-gen-qin-lian decoction for treatment of type 2 diabetes.

Authors:  Huiying Li; Linhua Zhao; Bo Zhang; Yuyu Jiang; Xu Wang; Yun Guo; Hongxing Liu; Shao Li; Xiaolin Tong
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-16       Impact factor: 2.629

10.  OAE: The Ontology of Adverse Events.

Authors:  Yongqun He; Sirarat Sarntivijai; Yu Lin; Zuoshuang Xiang; Abra Guo; Shelley Zhang; Desikan Jagannathan; Luca Toldo; Cui Tao; Barry Smith
Journal:  J Biomed Semantics       Date:  2014-07-05
View more
  5 in total

1.  Adverse drug reactions.

Authors:  Michael Rieder; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2015-09-20       Impact factor: 4.335

2.  GM604 regulates developmental neurogenesis pathways and the expression of genes associated with amyotrophic lateral sclerosis.

Authors:  William R Swindell; Krzysztof Bojanowski; Mark S Kindy; Raymond M W Chau; Dorothy Ko
Journal:  Transl Neurodegener       Date:  2018-12-03       Impact factor: 8.014

3.  A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies.

Authors:  Caroline Birer-Williams; Brandon T Gufford; Eric Chou; Marijanel Alilio; Sidney VanAlstine; Rachael E Morley; Jeannine S McCune; Mary F Paine; Richard D Boyce
Journal:  Drug Metab Dispos       Date:  2020-06-29       Impact factor: 3.922

4.  Database: A New Article Type in CPT: Pharmacometrics & Systems Pharmacology.

Authors:  L Li; P H van der Graaf
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-07-28

5.  Identification of Cysteine Protease Inhibitor CST2 as a Potential Biomarker for Colorectal Cancer.

Authors:  Qiurong Xie; Liya Liu; Xiaoping Chen; Ying Cheng; Jiapeng Li; Xiuli Zhang; Nanhui Xu; Yuying Han; Huixin Liu; Lihui Wei; Jun Peng; Aling Shen
Journal:  J Cancer       Date:  2021-06-22       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.